Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$34.40 USD
-0.78 (-2.22%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $34.38 -0.02 (-0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HRMY 34.40 -0.78(-2.22%)
Will HRMY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Other News for HRMY
Harmony Biosciences Holdings Inc (HRMY) to Announce Q2 2025 Financial Results | HRMY stock news
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 | HRMY ...
Truist Securities Initiates Coverage on Harmony Biosciences (HRMY) with Buy Rating | HRMY Stock News
Truist Initiates Buy Rating for Harmony Biosciences (HRMY) with Promising Growth Prospects | ...
Harmony Biosciences initiated with bullish view at Truist, here's why